肝硬化相关并发症白蛋白输注的国际立场声明
该国际立场声明由19个国家33名研究者通过三轮德尔菲共识流程制定,针对肝硬化相关并发症中人白蛋白(HA)的使用提出12条临床意义声明。声明推荐短期输注HA用于肝肾综合征、大量腹腔穿刺放液和自发性细菌性腹膜炎的管理;对其他并发症的预防或治疗作用需进一步阐明。长期HA给药可在特定情况下考虑,但需解决预算和后勤问题。接受HA输注的肝硬化患者应密切监测肺水肿这一潜在不良反应。
要点
- 短期输注人白蛋白推荐用于肝硬化肝肾综合征、大量腹腔穿刺放液和自发性细菌性腹膜炎的管理。
- 长期人白蛋白给药可在特定情况下考虑,但需在预算和后勤问题可解决的条件下。
- 接受人白蛋白输注的肝硬化患者应密切监测肺水肿这一潜在不良反应。
- 人白蛋白对其他肝硬化相关并发症的预防或治疗作用需进一步阐明。
- 人白蛋白的最佳时机和输注策略仍需进一步阐明。
适用人群与场景
- 肝硬化相关并发症患者,包括肝肾综合征、大量腹腔穿刺放液和自发性细菌性腹膜炎等场景。
处置流程与药物剂量
- 短期输注人白蛋白推荐用于肝肾综合征的管理。
- 短期输注人白蛋白推荐用于大量腹腔穿刺放液的管理。
- 短期输注人白蛋白推荐用于自发性细菌性腹膜炎的管理。
- 长期人白蛋白给药可在特定情况下考虑,但需在预算和后勤问题可解决的条件下。
- 接受人白蛋白输注的肝硬化患者应密切监测肺水肿。
红旗征与不能漏的情况
- 肺水肿是接受人白蛋白输注的肝硬化患者的潜在不良反应,应密切监测。
研究设计与关键结果
- 来自19个国家的33名研究者组成国际特别兴趣小组,通过三轮德尔菲共识流程制定关于人白蛋白用于肝硬化相关并发症治疗的立场声明。
- 共提出12条临床意义立场声明。
证据类型、等级与局限
- 证据类型:国际立场声明(德尔菲共识)。
- 局限:人白蛋白的最佳时机和输注策略仍需进一步阐明。
对床旁实践的改变
- 基于当前证据,短期人白蛋白输注应推荐用于肝肾综合征、大量腹腔穿刺放液和自发性细菌性腹膜炎的管理。
- 长期人白蛋白给药可在预算和后勤问题可解决的特定情况下考虑。
- 接受人白蛋白输注的肝硬化患者应密切监测肺水肿。
- 人白蛋白对其他肝硬化相关并发症的预防或治疗作用需进一步阐明。
指南或共识出处
- 国际立场声明:Use of albumin infusion for cirrhosis-related complications: An international position statement(JHEP Rep)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND & AIMS: Numerous studies have evaluated the role of human albumin (HA) in managing various liver cirrhosis-related complications. However, their conclusions remain partially controversial, probably because HA was evaluated in different settings, including indications, patient characteristics, and dosage and duration of therapy.
METHODS: Thirty-three investigators from 19 countries with expertise in the management of liver cirrhosis-related complications were invited to organise an International Special Interest Group. A three-round Delphi consensus process was conducted to complete the international position statement on the use of HA for treatment of liver cirrhosis-related complications.
RESULTS: Twelve clinically significant position statements were proposed. Short-term infusion of HA should be recommended for the management of hepatorenal syndrome, large volume paracentesis, and spontaneous bacterial peritonitis in liver cirrhosis. Its effects on the prevention or treatment of other liver cirrhosis-related complications should be further elucidated. Long-term HA administration can be considered in specific settings. Pulmonary oedema should be closely monitored as a potential adverse effect in cirrhotic patients receiving HA infusion.
CONCLUSIONS: Based on the currently available evidence, the international position statement suggests the potential benefits of HA for the management of multiple liver cirrhosis-related complications and summarises its safety profile. However, its optimal timing and infusion strategy remain to be further elucidated.
IMPACT AND IMPLICATIONS: Thirty-three investigators from 19 countries proposed 12 position statements on the use of human albumin (HA) infusion in liver cirrhosis-related complications. Based on current evidence, short-term HA infusion should be recommended for the management of HRS, LVP, and SBP; whereas, long-term HA administration can be considered in the setting where budget and logistical issues can be resolved. However, pulmonary oedema should be closely monitored in cirrhotic patients who receive HA infusion.
参考来源
- Bai Z, Méndez-Sánchez N, Romeiro FG, et al. Use of albumin infusion for cirrhosis-related complications: An international position statement. JHEP Rep. 2023. PMID: 37456673. doi:10.1016/j.jhepr.2023.100785
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。